OncologyEducation

Today is #CancerWellnessAwarenessDay. Wellness includes equitable access to cancer care. Explore practical strategies for delivering virtual cancer care with this free 30-minute CME (0.5 Mainpro+): bit.ly/4f9kiTx #VirtualCare #HealthEquity #CME

🚨 Schedule Update 🚨 ⏰ New Hours: 7:45 a.m.–3:00 p.m. EST Join us at #BestofASCO Toronto 2026 and enter for a chance to win Ray-Ban Meta Wayfarer Smart Glasses 🎁 📍 Draw: 12:55 p.m. #ASCO2026 #OncologyEducation

🎙️ New #MedOncNow Episode! Dr. Shaqil Kassam sits down with Dr. Howie Lim to discuss perioperative gastric cancer, emerging evidence, and evolving treatment strategies. Listen now. 🎧 #GastricCancer #Oncology #CancerCare #MedTwitter

🚨 Final day at #ASCO2026! This week we've seen advances in AI, blood-based biomarkers, immunotherapy, and precision oncology—all focused on delivering the right treatment to the right patient at the right time. Stay tuned for Day 4 highlights. 👇

🧬 @DrBetofMDPhD shares phase II results of OBX115, an engineered TIL therapy showing a 67% response rate in advanced melanoma, with a favorable safety profile and no need for systemic IL-2. bit.ly/4uPLFbQ #ASCO2026 #Melanoma

🧬 Dr. Paolo Ciracì presents an AI-powered histopathology biomarker that may help personalize upfront treatment decisions in metastatic colorectal cancer. bit.ly/4obI6dl

🎗️ Dr. Ghassan Abou-Alfa shares results from EMERALD-3, where adding STRIDE + TACE improved PFS to ~13 months versus 8–9 months with TACE alone in intermediate-stage HCC, supporting a potential new standard of care. bit.ly/4usskMV #ASCO2026

🧬 Dr. Elizabeth McDonald discusses research linking GLP-1 agonist use to a 30% lower incidence of breast cancer, highlighting a potential new avenue for cancer prevention. bit.ly/4dGC5lo #ASCO2026

🫁 Dr. Jamie Chaft reviews the EA5142 study, where adjuvant nivolumab showed no meaningful DFS benefit after surgery and chemotherapy, reinforcing the role of pre-operative chemoimmunotherapy in NSCLC. bit.ly/3QaAco1 #ASCO2026

👁️ Dr. Marlana Orloff shares OptimUM-02 findings showing darovasertib plus crizotinib improved outcomes in metastatic uveal melanoma, addressing a major unmet need for HLA-A2 negative patients. bit.ly/4nYgXug #ASCO2026 #Melanoma

🎗️ Dr. Shilpa Gupta discusses the phase III MAIN-CAV trial, where adding cabozantinib to avelumab maintenance showed no clear benefit in advanced urothelial cancer, while biomarker analyses continue. bit.ly/3PVs6PR #ASCO2026

📊 Dr. Claudio Vernieri presents PALMARES-2 data showing selected patients with HR+/HER2− advanced breast cancer may benefit from continuing first-line ET + CDK4/6 inhibition beyond progression. bit.ly/4feLNN0 #ASCO2026

🎗️ Dr. Lucy Gilbert shares subgroup analyses from the phase III ROSELLA trial, showing relacorilant maintained its survival benefit regardless of prior taxane exposure in platinum-resistant ovarian cancer. bit.ly/3RxsogB #ASCO2026

🤖 Dr. Paolo Ciracì highlights an AI-powered histopathology biomarker that may help identify which patients with metastatic colorectal cancer benefit most from upfront treatment intensification. bit.ly/4obI6dl #ASCO2026

🔬 Dr. Maggie Banys-Paluchowski presents AXSANA findings showing tumour biology—not the number of involved lymph nodes—is the strongest predictor of axillary response after neoadjuvant therapy. bit.ly/4x1oGM7 #ASCO2026

📈 Dr. Robert Stein discusses the OPTIMA trial, demonstrating that genomic testing can identify many patients with ER+/HER2− early breast cancer who may safely avoid chemotherapy. bit.ly/4u8UD2C #ASCO2026

🧬 Dr. Pavlos Msaouel presents findings supporting EGFR blockade in SMARCB1-deficient renal medullary carcinoma, offering a potential new treatment strategy for this rare disease. bit.ly/4fkHIXG #ASCO2026

🥗 Dr. Livia Augustin explores how Mediterranean diet, physical activity, and vitamin D may influence breast cancer recurrence and cardiometabolic health in a multicentre randomized study. bit.ly/4u8Uv38 #ASCO2026

🤝 Dr. Achim Wöckel reviews the BETTER-CARE trial, evaluating individualized, needs-based follow-up care for patients after primary breast cancer treatment. bit.ly/4ffN5aw #ASCO2026

🧬 @DrBetofMDPhD discusses phase II results of OBX-115, an engineered TIL therapy featuring membrane-bound IL-15, showing promising activity in advanced melanoma after immune checkpoint inhibitors. bit.ly/4uPLFbQ #ASCO2026